Pharmacokinetics, safety and tolerability of rotigotine transdermal patch in healthy Japanese and Caucasian subjects

Clinical Drug Investigation

Volumn 34, Issue 2, 2014, Pages 95-105

  Cawello, Willi ^a   Kim, Seong R ^b   Braun, Marina ^a   Elshoff, Jan Peer ^a   Ikeda, Junji ^b   Funaki, Tomoo ^b  

^a UCB PHARMA   (Belgium)

^b OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ROTIGOTINE;

ADULT; ARTICLE; BODY MASS; CAUCASIAN; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN EXPERIMENT; JAPANESE (PEOPLE); MALE; NORMAL HUMAN; OPEN STUDY; OUTCOME ASSESSMENT; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SINGLE DRUG DOSE; TRANSDERMAL PATCH;

ADMINISTRATION, CUTANEOUS; ADULT; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; DOPAMINE AGONISTS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HALF-LIFE; HUMANS; MALE; TETRAHYDRONAPHTHALENES; THIOPHENES; TRANSDERMAL PATCH; YOUNG ADULT;

EID: 84898939536     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.1007/s40261-013-0150-5     Document Type: Article

References (26)

1. Schapira AH. Science, medicine, and the future: Parkinson's disease. BMJ. 1999;318:311-4. (Pubitemid 29195142)
2. Rascol O, Goetz C, Koller W, Poewe W, Sampaio C. Treatment interventions for Parkinson's disease: an evidence based assessment. Lancet. 2002;359:1589-98. (Pubitemid 34621128)
3. Olanow CW, Jankovic J. Neuroprotective therapy in Parkinson's disease and motor complications: a search for a pathogenesis-targeted, disease-modifying strategy. Mov Disord. 2005;20:S3-10.
4. Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology. 2001;56:S1-88.
5. Bhatia K, Brooks DJ, Burn DJ, Clarke CE, Grosset DG, MacMahon DG, et al. Updated guidelines for the management of Parkinson's disease. Hosp Med. 2001;62:456-70. (Pubitemid 33791700)
6. Scholz H, Trenkwalder C, Kohnen R, Riemann D, Kriston L, Hornyak M. Dopamine agonists for restless legs syndrome. Cochrane Database Syst Rev. 2011;(3):CD006009.
7. Jenner P. A novel dopamine agonist for the transdermal treatment of Parkinson's disease. Neurology. 2005;65:S3-5. (Pubitemid 41022399)
8. Pfeiffer RF. A promising new technology for Parkinson's disease. Neurology. 2005;65:S6-10.
9. Cawello W, Wolff HM, Meuling WJ, Horstmann R, Braun M. Transdermal administration of radiolabelled [14C]rotigotine by a patch formulation: a mass balance trial. Clin Pharmacokinet. 2007;46:851-7. (Pubitemid 47443309)
10. Cawello W, Braun M, Boekens H. Absorption, disposition, metabolic fate, and elimination of the dopamine agonist rotigotine in man: administration by intravenous infusion or transdermal delivery. Drug Metab Dispos. 2009;37:2055-60.
11. Cawello W, Ahrweiler S, Sulowicz W, Szymczakiewicz-Multanowska A, Braun M. Single dose pharmacokinetics of the transdermal rotigotine patch in patients with impaired renal function. Br J Clin Pharmacol. 2012;73:46-54.
12. Parkinson Study Group. A controlled trial of rotigotine monotherapy in early Parkinson's disease. Arch Neurol. 2003;60:1721-8.
13. Watts RL, Jankovic J, Waters C, Rajput A, Boroojerdi B, Rao J. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology. 2007;68:272-6. (Pubitemid 46148338)
14. Giladi N, Boroojerdi B, Korczyn AD, Burn DJ, Clarke CE, Schapira AH. Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord. 2007;22:2398-404. (Pubitemid 351155987)
15. Poewe WH, Rascol O, Quinn N, Tolosa E, Oertel WH, Martignoni E, et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol. 2007;6:513-20. (Pubitemid 46734759)
16. LeWitt PA, Lyons KE, Pahwa R. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER study. Neurology. 2007;68:1262-7. (Pubitemid 46625971)
17. Trenkwalder C, Kies B, Rudzinska M, Fine J, Nikl J, Honczarenko K, et al. Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord. 2011;26:90-9.
18. Oertel WH, Benes H, Garcia-Borreguero D, Geisler P, Hogl B, Saletu B, et al. Efficacy of rotigotine transdermal system in severe restless legs syndrome: a randomized, double-blind, placebo-controlled, six-week dose-finding trial in Europe. Sleep Med. 2008;9:228-39. (Pubitemid 351391727)
19. Trenkwalder C, Benes H, Poewe W, Oertel WH, Garcia-Borreguero D, de Weerd AW, et al. Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2008;7:595-604.
20. Hening WA, Allen RP, Ondo WG, Walters AS, Winkelman JW, Becker P, et al. Rotigotine improves restless legs syndrome: a 6-month randomized, double-blind, placebo-controlled trial in the United States. Mov Disord. 2010;25:1675-83.
21. International Conference on Harmonisation; guidance on ethnic factors in the acceptability of foreign clinical data; availability - FDA. Notice. Fed Regist. 1998;63:31790-6.
22. Chen ML. Ethnic or racial differences revisited: impact of dosage regimen and dosage form on pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 2006;45:957-64.
23. Evidente VG, Esteban RP, Domingo FM, Carbajal LO, Parazo MA. Piribedil as an adjunct to levodopa in advanced Parkinson's disease: the Asian experience. Parkinsonism Relat Disord. 2003;10:117-21. (Pubitemid 37476318)
24. Hattori N. Appropriate dosing of pergolide in monotherapy and adjunctive therapy in Parkinson's disease. Curr Opin Neurol. 2003;16(Suppl 1):S21-5. (Pubitemid 38328110)
25. Rodrigues AD, Rushmore TH. Cytochrome P450 pharmacogenetics in drug development: in vitro studies and clinical consequences. Curr Drug Metab. 2002;3:289-309. (Pubitemid 34625041)
26. Elshoff J-P, Cawello W, Andreas J-O, Braun M. No influence of the CYP2C19-selective inhibitor, omeprazole, on the pharmacokinetics of the dopamine receptor agonist rotigotine. Clin Pharmacol Drug Dev. In Press.